Deepika Pakianathan, Director at Karyopharm Therapeutics Inc. (KPTI), sold 1,071,064 shares at $6.18 ($6.8M) on 2022-06-09, disclosed to the SEC on 2022-06-10.
Open-market sale of $6.8M KPTI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.50 | 3,152 | $20K | 0.3% |
| 2 | $6.50 | 322,825 | $2.1M | 30.7% |
| 3 | $6.50 | 322,825 | $2.1M | 30.7% |
| 4 | $6.18 | 2,045 | $13K | 0.2% |
| 5 | $6.18 | 209,455 | $1.3M | 19.0% |
| 6 | $6.18 | 209,455 |
| $1.3M |
| 19.0% |
| 7 | $6.00 | 13 | $78 | 0.0% |
| 8 | $6.00 | 1,294 | $8K | 0.1% |
| Total | $6.37 avg | 1,071,064 | $6.8M | 100% |
| Filing → |
| KPTI | SELL | 2024-06-04 | $1.4M | — | Filing → |
| CALA | SELL | 2023-01-31 | $47K | — | Filing → |
| KPTI | BUY | 2015-01-14 | $1.5M | — | Filing → |